Amanda Goldstein, MD
Family Medicine · Greenfield, INNPI 1437329786
Payments from drug & device makers
Across 186 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$474
- Pfizer$378
- Novo Nordisk$316
- GSK$232
- Astellas Pharma US Inc$206
- Lilly USA, LLC$197
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $474 |
| Pfizer | 23 | $378 |
| Novo Nordisk | 18 | $316 |
| GSK | 14 | $232 |
| Astellas Pharma US Inc | 10 | $206 |
| Lilly USA, LLC | 11 | $197 |
| Novartis | 12 | $191 |
| AstraZeneca | 10 | $152 |
| Boehringer Ingelheim | 7 | $139 |
| Phathom Pharmaceuticals, Inc. | 6 | $121 |
| Amgen | 6 | $102 |
| Arbor Pharmaceuticals, Inc. | 1 | $98 |
| Exact Sciences | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Bayer | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Abbott | 2 | $35 |
| Almatica Pharma LLC | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Verona Pharma, Inc. | 1 | $23 |
| Corium, LLC | 1 | $20 |
| Averitas Pharma Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
| Merck | 1 | $11 |
How this compares
$3,245 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $141,787 |
| FarxigaDapagliflozin Propanediol | 78 | $120,599 |
| EliquisApixaban | 103 | $91,838 |
| TrulicityDulaglutide | 41 | $76,362 |
| MounjaroTirzepatide | 58 | $60,337 |
| JardianceEmpagliflozin | 46 | $55,032 |
| MyrbetriqMirabegron | 58 | $54,967 |
| RybelsusSemaglutide | 28 | $48,084 |
| XareltoRivaroxaban | 44 | $43,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,125 |
| TradjentaLinagliptin | 30 | $25,385 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $23,589 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 64 | $19,721 |
| JanuviaSitagliptin Phosphate | 19 | $19,695 |
| Spiriva HandihalerTiotropium Bromide | 22 | $14,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $316 | $189,871149 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $197 | $136,69999 claims |
| AstraZenecaFarxiga | $152 | $120,59978 claims |
| PfizerEliquis, Lyrica, Paxlovid | $378 | $104,884129 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $139 | $92,39590 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix, Anoro Ellipta | $232 | $89,950191 claims |
| Astellas Pharma US IncMyrbetriq | $206 | $54,96758 claims |
| Johnson & JohnsonXarelto | $12 | $43,78344 claims |
| MerckJanuvia | $11 | $19,69519 claims |
| AbbVieLinzess | $474 | $14,16514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $67 | $6,09012 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,279387 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Greenfield
- Talessa PowellGreenfield$1.4M
- Thomas O'ConnorGreenfield$228K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.